Revolution Medicines Inc.
Revolution Medicines Announces Q2 2025 Financial Results and Progress
Summary
Revolution Medicines, Inc. reported its financial results for the quarter ended June 30, 2025, with highlights including a net loss of $247.8 million, R&D expenses of $224.1 million, and G&A expenses of $40.6 million. The company also shared updates on its clinical trials, including enrollment status and recent FDA Breakthrough Therapy Designations for its RAS(ON) inhibitors daraxonrasib and elironrasib. Additionally, the company announced a $2 billion funding agreement with Royalty Pharma.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement